Clinical Research Directory

Inclusion Criteria: Cohorts aRCC and aUBC (prospective) * Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic) * Patients at start of their first-line systemic treatment for aRCC or aUBC * Written informed consent * Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment * Patients not participating in the PRO module: within twelve weeks after start of systemic first-line for aRCC or aUBC * Age ≥ 18 years Cohort High-risk MIUC (prospective and retrospective) * Histologically proven muscle-invasive urothelial carcinoma (MIUC) of the lower or upper urinary tract (ICD-10 C65, C66, C67.x, C68.x). Mixed histologies are allowed (main compo-nent must be urothelial carcinoma, with minor variants accept-ed). * Radical surgery (e.g., radical cystectomy, nephroureterecto-my) between October 1, 2021 and October 31, 2024. * High-risk of recurrence, defined as follows: Post-operative, pathological tumor status * ypT2-ypT4 and/or ypN+ and without clinically detectable metastases (M0) at cystectomy for patients with prior neo-adjuvant chemotherapy or * pT3-pT4 and/or pN+ and without clinically detectable me-tastases (M0) at cystectomy for patients without prior neo-adjuvant chemotherapy. * Age ≥ 18 years at the time of surgery. * Written informed consent (only if patient is alive at time of data entry; not applicable for inclusion of deceased patients' data) Exclusion Criteria: Cohorts aRCC and aUBC (prospective) * Patients with prior systemic therapy for aRCC or aUBC * No systemic treatment for aRCC or aUBC Cohort High-risk MIUC (prospective and retrospective) * Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy * Metastatic disease (M1) at the time of surgery